Holen Sie sich die Stockscreener-App
1.30
1.52%
-0.02
Handel nachbörslich:
1.34
0.04
+3.08%
Schlusskurs vom Vortag:
$1.32
Offen:
$1.33
24-Stunden-Volumen:
324.98K
Relative Volume:
0.50
Marktkapitalisierung:
$149.85M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-24.22M
KGV:
-4.6445
EPS:
-0.2799
Netto-Cashflow:
$-17.13M
1W Leistung:
+3.17%
1M Leistung:
-7.14%
6M Leistung:
+26.21%
1J Leistung:
+18.18%
1-Tages-Spanne:
$1.30
$1.35
1-Wochen-Bereich:
$1.265
$1.375
52-Wochen-Spanne:
$0.88
$1.71
Cardiol Therapeutics Inc Stock (CRDL) Company Profile
Compare CRDL vs TAK, HLN, TEVA, ZTS, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CRDL
Cardiol Therapeutics Inc
|
1.30 | 152.16M | 0 | -24.22M | -17.13M | -0.2799 |
TAK
Takeda Pharmaceutical Co Adr
|
15.87 | 51.34B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.24 | 41.15B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.61 | 39.67B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
80.23 | 34.09B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
578.43 | 24.13B | 3.17B | 1.29B | 1.01B | 27.09 |
Cardiol Therapeutics Inc Stock (CRDL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-02 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-01-28 | Eingeleitet | Rodman & Renshaw | Buy |
| 2024-06-26 | Eingeleitet | ROTH MKM | Buy |
| 2024-04-22 | Eingeleitet | H.C. Wainwright | Buy |
Cardiol Therapeutics Inc Aktie (CRDL) Neueste Nachrichten
Cardiol Therapeutics (Nasdaq: CRDL) outlines 2026 virtual shareholder meeting - Stock Titan
CRDL Stock Price, Quote & Chart | CARDIOL THERAPEUTICS INC-A (NASDAQ:CRDL) - ChartMill
Cardiol Therapeutics Inc (TSX:CRDL) Stock Price & 30 Year Financial Data - GuruFocus
CCORF Maintains Cardiol Therapeutics(CRDL.US) With Buy Rating, Maintains Target Price $8 - Moomoo
(CRDL) On The My Stocks Page (CRDL:CA) - Stock Traders Daily
[SCHEDULE 13G/A] Cardiol Therapeutics Inc. Amended Passive Investment Disclosure - Stock Titan
Here's Why We're Watching Cardiol Therapeutics' (TSE:CRDL) Cash Burn Situation - Yahoo Finance
Cardiol Therapeutics Inc.Class A Common Shares (NQ: CRDL - FinancialContent
Stocks in play: Cardiol Therapeutics Inc. - The Globe and Mail
TradingKey - TradingKey
Cardiol Therapeutics to Present Pipeline at H.C. Wainwright BioConnect Conference at NASDAQ - TipRanks
Cardiol Therapeutics (CRDL) joins H.C. Wainwright BioConnect investor Fireside Chat at NASDAQ - Stock Titan
Cardiol Therapeutics to Participate in Fireside Chat at H.C. Wainwright 4th Annual BioConnect Investor Conference at the NASDAQ - PR Newswire
H.C. Wainwright Maintains Cardiol Therapeutics(CRDL.US) With Buy Rating, Maintains Target Price $9 - Moomoo
Cardiol Therapeutics Reports Higher Q1 2026 Loss but Stronger Cash Position - TipRanks
Cardiol Therapeutics (CRDL) extends cash runway and advances late-stage heart trials - Stock Titan
Cardiol Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Cardiol Therapeutics Inc expected to post a loss of 8 cents a shareEarnings Preview - TradingView
Cardiol Therapeutics’ Phase II MAvERIC Pericarditis Data Accepted by JAHA as Phase III Trial Nears Completion - TipRanks
Phase II MAvERIC data for CardiolRx in pericarditis to appear in JAHA for Cardiol (NASDAQ: CRDL) - Stock Titan
Cardiol Therapeutics' Phase II MAvERIC Results Accepted for Publication in the Journal of the American Heart Association - PR Newswire
Cardiol Therapeutics Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
CRDL.CA Stock Price, Quote & Chart | CARDIOL THERAPEUTICS INC-A (TSX:CRDL) - ChartMill
Phase III Trial Enrollment Reached (75%) for Promising Anti-Inflammatory and Anti-Fibrotic Cardiac Therapies by Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) - Barchart.com
Phase III Trial Enrollment Reached (75%) for Promising - openPR.com
User - The Chronicle-Journal
Ellis Martin Report: Cardiol Therapeutics (TSE.CRDL) CEO David Elsley on Breakthrough Heart Disease Treatment - ABN Newswire
Cardiol Therapeutics (CRDL) Expands MAVERIC Trial with New Clini - GuruFocus
Cardiol Therapeutics expands Phase III trial to 25 sites By Investing.com - Investing.com India
Cardiol Therapeutics expands Phase III trial to 25 sites - Investing.com UK
Cardiol Therapeutics Expands U.S. Phase III MAVERIC Trial Network as Enrollment Reaches 75% - TipRanks
Cardiol Therapeutics (NASDAQ: CRDL) expands U.S. MAVERIC Phase III trial network - Stock Titan
Cardiol Therapeutics Inc. Expands Maveric Phase III Trial Network and Provides Clinical Updates on Cardiolrx - marketscreener.com
Correction: Positive Results on MAVERIC Phase 2 and Published ARCHER Study Presented by the Company CEO in Live Interview with Barchart: Cardiol Therapeutics Inc. (NASDAQ: CRDL) - Barchart.com
Correction: Positive Results on MAVERIC Phase 2 and Published - openPR.com
Positive Results on MAVERIC Phase III Trial and Published ARCHER Study Presented by the Company CEO in Live Interview with Barchart: Cardiol Therapeutics Inc. (NASDAQ: CRDL) - Barchart
Positive Results on MAVERIC Phase III Trial and Published ARCHER - openPR.com
CRDL (Cardiol Therapeutics Inc.) Q4 2025 narrower than expected loss lifts shares more than 7 percent higher today.Revenue Diversification - Xã Thanh Hà
Is Cardiol (CRDL) stock sensitive to volatility (Drops Sharply) 2026-04-22Investment Community Signals - Cổng thông tin điện tử tỉnh Lào Cai
Metro Q2 2026 Earnings Rise On Margins, Buybacks And Pharmacy Growth - thedeepdive.ca
Moderna to Present at Upcoming Conferences in May 2026 - Investing News Network
Cardiol Therapeutics (TSE:CRDL) Sets New 1-Year HighHere's Why - MarketBeat
Fixing Heart Disease Tied to Sudden Death in Young People | David ElsleyCardiol Therapeutics - thedeepdive.ca
Cardiol Therapeutics (TSE:CRDL) Trading Up 7.9%Here's What Happened - MarketBeat
Cardiol Therapeutics CEO: Phase III MAVERIC Nears Full Enrollment as CardiolRx Shows Myocarditis Promise - MarketBeat
Finanzdaten der Cardiol Therapeutics Inc-Aktie (CRDL)
Umsatz
Nettogewinn
Free Cashflow
ENV
5.02%
5.78%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):